Porphyria Cutanea Tarda (PCT) in a Patient, Treated with Hemodialysis after a Kidney Transplant Rejection Reaction: A Case Report
Article Sidebar
Main Article Content
Abstract
Porphyrias are a group of inherited metabolic disorders of haem biosynthesis, involving a deficiency in the enzyme uroporphyrinogen decarboxylase. In this case report we present a case of a patient with porphyria cutanea tarda (PCT). A 40-year-old man on hemodialysis after a kidney transplant rejection reaction, complaining of skin changes, with a history of smoking and alcohol intake. Treated with Fusidic acid Betamethasone cream, and erythropoietin. Porhyria cutanea tarda can be considered in a patient who complains of skin changes. History of alcohol intake, smoking, high ferritin levels, and increased hepatic markers can raise suspicion of disease. In patients with ESRD treatment with erythropoietin, SPF 50+ sun cream, Fusidic acid, and Betamethasone can be effective.
Article Details
Copyright (c) 2024 Stasilo R, et al.
This work is licensed under a Creative Commons Attribution 4.0 International License.
The Journal of Clinical Nephrology is committed in making it easier for people to share and build upon the work of others while maintaining consistency with the rules of copyright. In order to use the Open Access paradigm to the maximum extent in true terms as free of charge online access along with usage right, we grant usage rights through the use of specific Creative Commons license.
License: Copyright © 2017 - 2025 | 
Open Access by Journal of Clinical Nephrology is licensed under a Creative Commons Attribution 4.0 International License. Based on a work at Heighten Science Publications Inc.
With this license, the authors are allowed that after publishing with the journal, they can share their research by posting a free draft copy of their article to any repository or website.
Compliance 'CC BY' license helps in:
| Permission to read and download | ✓ |
| Permission to display in a repository | ✓ |
| Permission to translate | ✓ |
| Commercial uses of manuscript | ✓ |
'CC' stands for Creative Commons license. 'BY' symbolizes that users have provided attribution to the creator that the published manuscripts can be used or shared. This license allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to the author.
Please take in notification that Creative Commons user licenses are non-revocable. We recommend authors to check if their funding body requires a specific license.
Puy H, Gouya L, Deybach JC. Porphyrias. Lancet. 2010 Mar 13;375(9718):924-37. doi: 10.1016/S0140-6736(09)61925-5. PMID: 20226990.
Muschalek W, Hermasch MA, Poblete-Gutiérrez P, Frank J. The Porphyrias. J Dtsch Dermatol Ges. 2022 Mar;20(3):316-331. doi: 10.1111/ddg.14743. PMID: 35304965.
Chan OT, Tsai N, Wong RL, Izumi AK. The additive effects of hepatitis C infection and end-stage renal disease in porphyria cutanea tarda. Cutis. 2006 Dec;78(6):397-400. PMID: 17243426.
Singal AK. Porphyria cutanea tarda: Recent update. Mol Genet Metab. 2019 Nov;128(3):271-281. doi: 10.1016/j.ymgme.2019.01.004. Epub 2019 Jan 18. PMID: 30683557.
Rodrigues N, Caeiro F, Santana A, Mendes T, Lopes L. Porphyria Cutanea Tarda in a Patient with End-Stage Renal Disease: A Case of Successful Treatment with Deferoxamine and Ferric Carboxymaltose. Case Rep Nephrol. 2017; 2017:4591871. doi: 10.1155/2017/4591871. Epub 2017 Jan 22. PMID: 28210512; PMCID: PMC5292176.
Weiss Y, Chen B, Yasuda M, Nazarenko I, Anderson KE, Desnick RJ. Porphyria cutanea tarda and hepatoerythropoietic porphyria: Identification of 19 novel uroporphyrinogen III decarboxylase mutations. Mol Genet Metab. 2019 Nov;128(3):363-366. doi: 10.1016/j.ymgme.2018.11.013. Epub 2018 Nov 28. PMID: 30514647; PMCID: PMC8132452.
Pallet N, Karras A, Thervet E, Gouya L, Karim Z, Puy H. Porphyria and kidney diseases. Clin Kidney J. 2018 Apr;11(2):191-197. doi: 10.1093/ckj/sfx146. Epub 2018 Jan 10. PMID: 29644058; PMCID: PMC5888040.
Tang Z, Ma J, Wang L, Shi Z. Porphyria cutanea tarda associated with alcohol abuse: three case reports. Preprints; 2022 Jul [cited 2024 Mar 14]. https://www.authorea.com/users/494199/articles/576343-porphyria-cutanea-tarda-associated-with-alcohol-abuse-three-case-reports?commit=989ce8f8e16e3c5ead989839f62a862c2a72e288
Egger NG, Goeger DE, Payne DA, Miskovsky EP, Weinman SA, Anderson KE. Porphyria cutanea tarda: multiplicity of risk factors including HFE mutations, hepatitis C, and inherited uroporphyrinogen decarboxylase deficiency. Dig Dis Sci. 2002 Feb;47(2):419-26. doi: 10.1023/a:1013746828074. PMID: 11855561.
Usta Atmaca H, Akbas F. Porphyria cutanea tarda: a case report. J Med Case Rep. 2019 Jan 21;13(1):17. doi: 10.1186/s13256-018-1956-9. PMID: 30661508; PMCID: PMC6340172.
Lee KG, Hyun JJ, Seo YS, Keum B, Yim HJ, Jeen YT, Lee HS, Chun HJ, Kim CD, Ryu HS, Um SH. Liver cirrhosis induced by porphyria cutanea tarda: a case report and review. Gut Liver. 2010 Dec;4(4):551-5. doi: 10.5009/gnl.2010.4.4.551. Epub 2010 Dec 17. PMID: 21253308; PMCID: PMC3021615.
Sarkany RP. The management of porphyria cutanea tarda. Clin Exp Dermatol. 2001 May;26(3):225-32. doi: 10.1046/j.1365-2230.2001.00825.x. PMID: 11422163.
Shieh S, Cohen JL, Lim HW. Management of porphyria cutanea tarda in the setting of chronic renal failure: a case report and review. J Am Acad Dermatol. 2000 Apr;42(4):645-52. PMID: 10727312.
Huang YC, Wang CC, Sue YM. Porphyria cutanea tarda in a hemodialysis patient. QJM. 2013 Jun;106(6):591-2. doi: 10.1093/qjmed/hcs115. Epub 2012 Jun 28. PMID: 22753666.
Bissell DM, Anderson KE, Bonkovsky HL. Porphyria. N Engl J Med. 2017 Aug 31;377(9):862-872. doi: 10.1056/NEJMra1608634. PMID: 28854095.